Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.1419901111 http://scihub22266oqcxt.onion/10.1073/pnas.1419901111 C4273328!4273328!25422468     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2014 ; 111 (50): E5420-8 Nephropedia Template TP {{tp|p=25422468|t=2014. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy |pdf=|usr=}}{{25422468}} gab.com Text Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=25422468 #FOAvip Diabetic nephropathy is the leading cause of chronic kidney disease in the United States, and one of the most significant long-term complications of both type 1 and type 2 diabetes, which currently lack fully effective therapy. Hyperglycemia and activation of the renin-angiotensin system (RAS) are thought to be the two main drivers of this pathology. We have recently shown that selective blockade of peripheral cannabinoid receptor-1 (CB1R) delayed and attenuated the development of type 2 diabetes in a rat model. Here we show that the nephropathy-inducing effects of both hyperglycemia and activation of the RAS involve CB1R activation in glomerular podocytes, and that antagonism of peripheral CB1R could represent a novel, effective, and rational approach to both prevent and reverse diabetic nephropathy. Twit Text FOAVip Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=25422468 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25422468 #FOAvip English Wikipedia <ref>{{Cite pmid|25422468}}</ref> Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy #MMPMID25422468 Jourdan T; Szanda G; Rosenberg AZ; Tam J; Earley BJ; Godlewski G; Cinar R; Liu Z; Liu J; Ju C; Pacher P; Kunos G Proc Natl Acad Sci U S A 2014[Dec]; 111 (50): E5420-8 PMID25422468show ga Diabetic nephropathy is the leading cause of chronic kidney disease in the United States, and one of the most significant long-term complications of both type 1 and type 2 diabetes, which currently lack fully effective therapy. Hyperglycemia and activation of the renin-angiotensin system (RAS) are thought to be the two main drivers of this pathology. We have recently shown that selective blockade of peripheral cannabinoid receptor-1 (CB1R) delayed and attenuated the development of type 2 diabetes in a rat model. Here we show that the nephropathy-inducing effects of both hyperglycemia and activation of the RAS involve CB1R activation in glomerular podocytes, and that antagonism of peripheral CB1R could represent a novel, effective, and rational approach to both prevent and reverse diabetic nephropathy. äOveractive cannabinoid 1 receptor in podocytes drives type 2 diabetic (epmc).pdf DeepDyve Pubget Overpricing